Browse the evidence

High consumption of sugar-sweetened beverages (≥2 servings/day) increases cardiovascular disease risk by 15% even in individuals who meet physical activity guidelines.

If you drink two or more sugary beverages a day, your cardiovascular risk remains elevated even if you exercise regularly. While exercise is crucial for health, it does not completely cancel out the negative effects of high sugar intake. To minimize heart disease risk, limit sugary drinks regardless of your activity level.

Not meeting physical activity guidelines combined with high consumption of sugar-sweetened beverages (≥2 servings/week) is associated with a 47% higher risk of cardiovascular disease.

If you are not physically active, drinking sugary beverages frequently (≥2 servings/week) significantly increases your risk of heart disease. To lower your risk, you should aim to increase physical activity and reduce sugary drink intake.

Effective obesity medications (e.g., GLP-1/GIP agonists) work by lowering the adipose mass set point through counteracting adaptive hormonal responses, allowing homeostasis at a lower weight, but require lifelong use to maintain this new set point.

Obesity medications are not a temporary fix but a long-term management tool for a chronic disease. They work by resetting your body's biological 'thermostat' to a lower weight. If you stop taking them, your biology will fight to regain the weight. Therefore, these medications should be viewed as lifelong treatments, similar to blood pressure medication, to maintain your health.

Metabolic adaptation during weight loss involves a 15-20% reduction in daily energy expenditure beyond what is expected from mass loss, which persists until the previous weight is regained.

When you lose weight through dieting, your body burns 15-20% fewer calories than expected for your new size. This 'metabolic adaptation' does not go away over time; it stays until you regain the weight. This is why maintaining weight loss through diet alone is so difficult—you must eat significantly less than a healthy person of your new weight would.

GLP-1 receptor agonists (GLP-1RAs) reduce binge eating frequency and severity in patients with Binge Eating Disorder (BED) and Bulimia Nervosa (BN), likely by modulating central reward circuits and increasing satiety.

If you have BED or BN, GLP-1RAs like semaglutide or liraglutide can significantly reduce binge eating episodes by changing how your brain responds to food rewards and increasing fullness. This is supported by systematic reviews, though it is not a standalone cure and should be monitored by a clinician, especially given potential gastrointestinal side effects.

GLP-1 receptor agonists (semaglutide, tirzepatide) are highly effective pharmacologic interventions for obesity, producing significant weight loss and metabolic improvements, but their rapid expansion raises safety concerns regarding gastrointestinal side effects, rare serious adverse events, and long-term outcomes not captured in clinical trials.

GLP-1 medications like semaglutide and tirzepatide are currently the most effective non-surgical treatments for obesity, offering weight loss comparable to surgery for many. However, they are not without risks, including common gastrointestinal issues and rare serious side effects. It is crucial to use these medications under strict medical supervision, especially if you have other health conditions, to manage side effects and monitor for long-term safety.

Standard body composition metrics (DXA) overestimate muscle loss in obesity because they misclassify visceral and subcutaneous fat as 'lean body mass'; MRI-based 'adipose tissue-free muscle volume' provides a more accurate assessment of true muscle mass.

If you are using DXA scans to track muscle loss on GLP-1s, be aware that these machines often mistake visceral fat for muscle. This can make it look like you are losing more muscle than you actually are. Focus on functional strength (grip, lifting) rather than just the DXA number.

Fixed-ratio combinations (FRCs) of basal insulin and GLP-1 receptor agonists (GLP-1RA) provide superior glycemic control and weight loss compared to either component alone, but are limited by a low GLP-1RA dose relative to the insulin dose, making separate dosing preferable for obese patients requiring higher GLP-1RA doses.

Fixed-ratio combinations (like IDegLira, iGlarLixi, or IcoSema) are effective for lowering blood sugar and weight compared to using just insulin or just a GLP-1 drug. However, because the ratio of insulin to GLP-1 drug is fixed, these combinations often deliver too little GLP-1 drug for obese patients who need higher doses for maximum weight loss and glucose control. If you are obese or need high doses of GLP-1RA, separate injections of basal insulin and GLP-1RA allow you to titrate each drug independently to your optimal dose.

Roux-en-Y gastric bypass (RYGB) and Health Behavior Intervention (HBI) are cost-effective strategies for managing class III obesity, whereas current-price pharmacotherapies (semaglutide and tirzepatide) are not cost-effective compared to no treatment or HBI.

For individuals with class III obesity, Roux-en-Y gastric bypass offers the best long-term health outcomes and cost-effectiveness. Health Behavior Intervention (13 counseling sessions) is also cost-effective. Current GLP-1/GIP medications are not cost-effective at current prices, though lower prices could change this.

Antiobesity medications (AOMs) improve cardiovascular outcomes, hypertension, and metabolic liver disease in older adults, but their use requires caution due to an increased risk of sarcopenia.

For older adults, AOMs are a powerful tool to treat obesity-related health issues like heart disease and diabetes. However, because losing weight can also lead to muscle loss (sarcopenia), these medications should be used cautiously and monitored closely by a doctor, often alongside lifestyle changes.

Higher postprandial endogenous GLP-1 release is positively correlated with hepatic and peripheral insulin sensitivity in individuals with class II/III obesity without diabetes, and this association persists one year after Roux-en-Y gastric bypass (RYGB).

For individuals with obesity, higher natural GLP-1 responses to meals are linked to better insulin sensitivity. While Roux-en-Y gastric bypass significantly amplifies this GLP-1 response, leading to improved metabolic health, the study suggests that the magnitude of this hormonal response is a key indicator of metabolic status. Non-surgical strategies that might support healthy incretin responses (though not explicitly detailed in this paper) could be beneficial, but the data strongly links the specific postprandial GLP-1 profile to insulin sensitivity.

Shifting nutrient absorption to the distal small intestine (ileum) significantly increases post-prandial GLP-1 and PYY secretion, improving glucose control and contributing to weight loss, as seen in bariatric surgery and with certain enzyme inhibitors.

Bariatric surgery works partly by forcing food to be digested further down the intestine, which triggers a strong hormone release (GLP-1/PYY) that helps control blood sugar and appetite. Some diabetes medications (like acarbose) mimic this by slowing digestion. This suggests that how and where food is absorbed matters as much as what is eaten.

GLP-1 receptor agonists (GLP-1RA) significantly reduce body weight and visceral fat, leading to improved cardiovascular and renal outcomes in T2DM patients.

For T2DM patients with heart or kidney risks, GLP-1 receptor agonists are a top choice. They help lower blood sugar, promote significant weight loss by reducing visceral fat, and protect the heart and kidneys. Discuss options like weekly injections or oral formulations with your doctor.

GLP-1 receptor agonists (specifically liraglutide and semaglutide) reduce cardiovascular risk and may induce atherosclerotic plaque regression in patients with diabetes-associated atherosclerosis.

If you have diabetes and heart disease risk, ask your doctor about GLP-1 agonists like liraglutide or semaglutide. They don't just lower blood sugar; they protect your heart and may shrink arterial plaques. These are injectable drugs, but they offer significant cardiovascular benefits that oral medications may not.

The presence of obesity-related complications (e.g., Type 2 Diabetes, Hypertension) significantly amplifies medical costs, with costs up to 5.2 times higher for those with multiple complications compared to obesity alone.

Having obesity-related complications like Type 2 Diabetes or Hypertension drastically increases medical costs (up to 5.2x). This underscores the importance of not just losing weight, but also managing these specific conditions to control overall healthcare spending.

Tirzepatide, a dual GIP/GLP-1 receptor agonist, significantly reduces Obstructive Sleep Apnea (OSA) severity (measured by AHI) and improves cardiometabolic risk factors in patients with obesity and moderate-to-severe OSA.

If you have obesity and moderate-to-severe sleep apnea, Tirzepatide is a newly approved medication that can significantly reduce the severity of your apnea (AHI) and improve blood pressure and inflammation. It works primarily by promoting weight loss and potentially affecting brain pathways related to breathing control. Because stopping the drug leads to weight regain, it is likely a long-term treatment. It is not a substitute for PAP therapy in all cases, but it is a powerful new tool, especially for those who struggle with CPAP adherence.

Combining CPAP with weight loss (via pharmacotherapy or lifestyle) yields greater improvements in cardiovascular risk profiles (specifically systolic blood pressure) than either treatment alone.

If you use CPAP for sleep apnea, adding weight loss (through diet, exercise, or medications like Tirzepatide) provides extra protection for your heart and blood pressure that CPAP alone does not offer. The combination is superior to either treatment by itself.

Resistance training does not reduce flexibility; this is a common myth.

You do not need to fear that lifting weights will make you stiff. Resistance training, when performed through a full range of motion, does not reduce flexibility and can be part of a balanced fitness routine.

Low-load, high-volume resistance training is as effective as high-load resistance training for maximizing strength.

If your goal is to get stronger (maximal strength), you need to lift heavier loads. Lighter weights with high repetitions are not as effective for this specific goal.

Long-term use of FDA-approved GLP-1/GIP agonists (tirzepatide and semaglutide) produces significant weight loss and metabolic improvements in real-world populations, though efficacy is lower than in randomized clinical trials due to conservative dosing and adherence issues.

Tirzepatide and semaglutide are highly effective for weight loss in real-world settings, but results vary. Expect that only about 1/3 to 2/5 of users will lose 10% of their body weight, even with long-term use. This is lower than clinical trial promises due to lower real-world doses and adherence. Consistency and appropriate dosing are key.

Discontinuation of FDA-approved GLP-1/GIP agonists (tirzepatide, semaglutide) does not lead to significant weight regain at the population level, contrasting with off-label drugs like phentermine and zonisamide which cause substantial regain.

If you stop taking tirzepatide or semaglutide, you are not guaranteed to regain all the weight immediately. Studies show that some weight loss benefit may persist for up to two years. This is different from older drugs like phentermine, where regain is common.

There is significant individual variability in response to all anti-obesity medications, with a substantial subset of patients experiencing weight gain or failing to achieve target weight loss, regardless of the drug class.

Not everyone responds to weight loss drugs the same way. Some people gain weight even on strong medications like tirzepatide. If you don't see results, it may be due to individual biological differences, not just effort. Discuss switching medications with your doctor.

When total training volume is equated, resistance training performed 3 times per week produces greater absolute strength gains than 4 times per week in young men.

If you are training 4 days a week and not seeing strength gains, check your volume. If you are already doing enough total work, switching to 3 days a week might actually help you get stronger, provided you keep the total sets and reps the same. Do not just add a 4th day on top of your current routine expecting better results; consolidate your volume into fewer sessions.

Training frequency does not significantly impact muscle hypertrophy (measured by circumference) when total training volume is equated.

If your goal is muscle size, focus on hitting your total weekly sets and reps, not how many days you train. Whether you train 3 or 4 days a week, as long as the total volume is the same, your muscle growth will be similar. Do not feel pressured to add extra days just for the sake of frequency.